Capivasertib (Truqap™) | OncoLink
ويبFulvestrant bloquea los receptores de estrógeno en el tejido mamario, lo que ralentiza o detiene el crecimiento del cáncer. Consulte la hoja de medicamentos para fulvestrant en OncoLink.org.
مزید دریافت کریں
Capivasertib (Truqap™) | OncoLink
ويب29 نومبر، 2023 · Capivasertib is often given in combination with a medication called fulvestrant, which is given as an injection in a muscle (intramuscular or IM). Fulvestrant blocks estrogen receptors in breast tissue, slowing or stopping cancer growth. Please see the medication sheet for fulvestrant at OncoLink.org.
- لوگ بھی پوچھتے ہیں
Pan-AKT Inhibitor Capivasertib With Docetaxel and …
ويب16 دسمبر، 2020 · Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic castration-resistant prostate cancer (mCRPC) and …
- Author: Simon J Crabb, Simon J Crabb, Gareth Griffiths, Gareth Griffiths, Ellice Marwood, Ellice Marwood, De...
- Publish Year: 2021
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
ويب1 جون، 2023 · Capivasertib–fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone re-ceptor–positive advanced...
EMA Recommends Granting a Marketing Authorisation for
ويب29 اپریل، 2024 · Capivasertib selectively inhibits all isoforms of AKT (AKT1, AKT2 and AKT3) hampering downstream proliferation signaling and thereby reducing the growth of tumour cells.
Capivasertib in Advanced Breast Cancer | New England Journal of …
ويب31 مئی، 2023 · Appropriate endocrine therapy is unclear for hormone receptor–positive, HER2-negative advanced breast cancer that progresses despite treatment with an aromatase inhibitor with or without a CDK4/6...
ويب16 اپریل، 2021 · In this clinical study, which selectively targeted the aggressive PTEN-mutant ER+ MBC, capivasertib plus fulvestrant was tolerable and clinically active.
“The emerging role of capivasertib in breast cancer” - PMC
ويب1 اپریل، 2022 · Capivasertib (AZD5363) is a highly potent Akt kinase inhibitor with activity against the three isoforms AKT1, AKT2, and AKT3. •. Preclinical studies demonstrated efficacy of capivasertib either alone or in combination with anti-HER2 agents, chemotherapy and endocrine treatment. •.
A phase I study of capivasertib in combination with abiraterone …
ويب2 مارچ، 2021 · We report interim results of a phase 1 multicohort study (NCT04087174) to confirm the acceptable dose of capivasertib, a potent, selective pan-AKT inhibitor in combination with the androgen synthesis inhibitor abiraterone acetate (AA) in mCRPC patients.
A phase III trial of capivasertib and paclitaxel in first-line ...
ويبThe phase II PAKT study (NCT02423603) demonstrated that addition of the oral AKT inhibitor capivasertib to first-line paclitaxel resulted in significantly longer progression-free survival (PFS) and overall survival (OS) in patients with advanced TNBC, especially in patients with PIK3CA/AKT1/PTEN-altered tumors (Schmid et al, 2019).
مشمول پر چھوڑیں